Britannia Pharmaceuticals Limited

Private and voluntary organisations · Private limited company

Pin Request correction

First report 18 Jul 2024•Latest report 18 Jul 2024

Reports, concerns and published responses

Reports over time

Reports naming this recipient by issue year.

* 2026 is projected from reports observed to 7 Sep 2026.

Reports
1

Naming this recipient

Published responses
100%

Found for named reports

Concerns addressed
1

Across all linked responses

Stated actions
0

Described in responses

Concerns and recipient responses

Statements from Britannia Pharmaceuticals Limited linked to the concerns in each report. Select any concern, action or position to view the source wording.

  1. Manchester South

    AI-generated summary

    Sasha Drysdale · Prevention of Future Deaths report

    This summary was generated using AI from the published report. Please read the original report for the complete account.

    Report summary

    Sasha Drysdale died on 28 March 2023 in hospital as a consequence of acute myeloid leukaemia transformed from myelodysplastic syndrome. She had previously been prescribed clozapine for treatment-resistant schizoaffective disorder and was detained under section 3 of the Mental Health Act 1983 at the time of her death. The concern raised was that further research is needed to establish whether clozapine materially increases the risk of certain blood cancers.

    Read the report on judiciary.uk

    Source evidence

    How this individual concern was interpreted

    PFD Monitor created a concise, searchable interpretation from the report wording shown below. The report was sent to Britannia Pharmaceuticals Limited; that does not assign responsibility.

    PFD Monitor interpretation

    Potential increased risk of certain blood cancers among patients taking Clozapine

    Wider context from the report

    “The court heard evidence as to a small number of studies conducted internationally which, whilst having small sample sizes, could be read as suggesting an increased incidence of certain forms of blood cancer amongst those taking Clozapine. I am concerned that further research is needed to either refute or confirm whether or not taking Clozapine materially increases the risk of a patient developing certain blood cancers. ”
    Open source report

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    A causal relationship between clozapine and blood cancer has not been established or confirmed by current evidence.

    Verbatim wording from the response

    “A causal relationship between Clozapine therapy and blood cancer (leukaemia) is at the current state of scientific knowledge not established and therefore not referenced in the SmPC.”

    Source location

    Response from Britannia Pharmaceuticals Ltd
    Page 2 · response
    Published 31 July 2024

    Open published response

    Source evidence

    How this respondent position was interpreted

    PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

    PFD Monitor interpretation

    The slightly increased blood-cancer risk associated with clozapine is outweighed by its overall reduction in mortality.

    Verbatim wording from the response

    “• A statistically calculated slightly increased risk of Blood Cancer in Clozapine patients is outweighed by the overall reduction in mortality by Clozapine treatment.”

    Source location

    Response from Britannia Pharmaceuticals Ltd
    Page 3 · response
    Published 31 July 2024

    Open published response
Back to top

Information checked against published PFD reports and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Data last updated 7 September 2026